Voluntis this week launched an upgraded version of Insulia, its digital therapeutic designed to give automated basal insulin dose recommendations and coaching messages for people with Type 2 diabetes.
The company touted that its upgraded version of Insulia improves user experience and offers Spanish programming.
“Over the past year, we’ve worked closely with the medical community and people with diabetes using Insulia to understand how we can further help meet their needs,” Ellie Strock, VP of U.S. medical affairs, said in prepared remarks. “The beauty of digital therapeutics like Insulia is that we can use this feedback to continuously improve them, making insulin management ever easier.”
Voluntis’ Insulia includes a web portal for healthcare practitioners to set up personalized treatment plans for their patients. Users receive a personalized app that uses blood glucose readings and symptoms of hypoglycemia to recommend insulin doses in real-time, according to Voluntis. User data is automatically shared with a healthcare team, who remotely monitor the user’s progress.
The Insulia program is compatible with Lantus, Levemir, Toujeo, Tresiba (U-100) and Basaglar basal insulins.